DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for Aicardi-Goutieres syndrome — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAicardi-Goutieres syndrome maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for aicardi-goutieres syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1 (SAMHD1) — SAMHD1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8QXJ · 2.65 Å · ligand 2'-deoxy-5'-O-[(R)-hydroxy{[(R)-hydroxy(phosphonooxy)phosphoryl]amino}phosphoryl]adenosine (DZ4). Experimental structure, not a prediction.
What the evidence adds up to
A 2019 review of treatments for Aicardi–Goutières syndrome notes that progress in understanding disease pathogenesis has led to the first attempts at targeted treatment, and that further rational therapies are expected in the short to medium term. The review summarises neurological phenotypes associated with mutations in the seven known AGS genes, discusses pathology as it relates to possible treatment approaches, and critically appraises the potential utility of therapies. It also highlights the challenges in assessing clinical efficacy.
A separate 2019 report on developmental outcomes in AGS, published as supplemental material, does not provide treatment data or numerical outcomes in the abstract.
A 2019 case report of two Syrian siblings with AGS type 2 (gene locus 13q14.3) describes the condition as an autosomal recessively inherited, early manifesting, rapid progressive encephalopathy with clinical and genetic heterogeneity, regarded as underdiagnosed due to low incidence and atypical clinical manifestation. No treatment or outcome data are given in the abstract.
No controlled trial data, survival figures, or response rates are reported in any of these abstracts. What remains missing is any completed clinical trial demonstrating efficacy, a standardised outcome measure for AGS, and sufficient patient numbers to stratify by genotype or disease severity.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Developmental Medicine & Child Neurology · 2019 · 114 citations · open access
Treatments in Aicardi–Goutières syndrome
AbstractComprehensive reviews of the clinical characteristics and pathogenesis of Aicardi-Goutières syndrome (AGS), particularly its contextualization within a putative type I interferonopathy framework, already exist. However, recent reports of attempts at treatment suggest that an assessment of the field from a therapeutic perspective is warranted at this time. Here, we briefly summarize the neurological phenotypes associated with mutations in the seven genes so far associated with AGS, rehearse current knowledge of the pathology as it relates to possible treatment approaches, critically appraise the potential utility of therapies, and discuss the challenges in assessing clinical efficacy. WHAT THIS PAPER ADDS: Progress in understanding AGS disease pathogenesis has led to the first attempts at targeted treatment. Further rational therapies are expected to become available in the short- to medium-term.
Sage Journals Data · 2019 · 0 citations · open access
Supplemental Material, Supplemental_Material-_Table_2 - Developmental Outcomes of Aicardi Goutières Syndrome
AbstractSupplemental Material, Supplemental_Material-_Table_2 for Developmental Outcomes of Aicardi Goutières Syndrome by Laura Adang, Francesco Gavazzi, Micaela De Simone, Elisa Fazzi, Jessica Galli, Jamie Koh, Julia Kramer-Golinkoff, Valentina De Giorgis, Simona Orcesi, Kyle Peer, Nicole Ulrick, Sarah Woidill, Justine Shults and Adeline Vanderver in Journal of Child Neurology
Aicardi-Goutières Syndrome 2 - Case Reports of 2 Siblings
AbstractQuestion: Aicardi-Goutières Syndrome (AGS) is an autosomal recessively inherited, early manifesting, rapid progressive encephalopathy with clinical and genetic heterogeneity, which is regarded as underdiagnosed, due to its low incidence and atypical clinical manifestation. 4 genetic variations (AGS 1 – AGS 4) are known. We present two Syrian siblings with the diagnosis of AGS 2 (gene locus 13q14.3).
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
